ETEST®
Antibiotic Susceptibility Testing Reagent Strips to Determine On-Scale MICs
Clinicians often need more information than what primary AST can provide. Recognized around the world for their proven performance, ETEST® ready to use reagent strips determine on-scale MICs.
Disclaimer: Product availability varies by country. Please consult your local bioMérieux representative for product availability in your country.
- Overview
- Specs & Resources
Overview
Proven Medical Value in the Face of Growing Resistance
ETEST® strips is the original gradient MIC strips. The strips consistently maintain their reliability when it comes to establishing the on-scale Minimum Inhibitory Concentration (MIC) of antibiotics and antifungal agents. ETEST® is a predefined, stable gradient of 15 antimicrobial concentrations on a plastic strip. ETEST® has an extensive range of over 90 antimicrobial references available in the following categories: antibiotics, antifungals, and antimicrobial resistance detection (ARD).
ETEST® is a simple, cost-effective tool that offers MIC results to complement your routine antimicrobial susceptibility tests (AST) performed on VITEK® 2 systems, or other automated platforms or manual testing (Kirby-Bauer method) allowing you to:
- Test new/non-routine antimicrobials
- Determine the MIC of fastidious, or slow-growing micro-organisms
- Confirm or detect low-level or new resistance mechanisms
- Fine-tune antimicrobial treatment
The Trusted Original Gradient MIC Strips
Did you know?
Versatile & Flexible: The Method of Choice to Supplement Your Main Primary Routine AST System
ETEST® is an accurate solution for completing the AST profile:
- For new antimicrobials that are not accessible in a routine mode
- For difficult organisms that can’t be tested by primary AST methods (e.g., fastidious, anaerobic, primary AST limitations, etc.)
- For drug/bug combinations that are not available
ETEST® fills gaps that primary testing cannot cover:
- Detecting low levels of resistance or new resistance mechanisms
- Fine-tuning antimicrobials treatment (MDROs, drug with narrow therapeutic index, critically ill patients, breakpoints zone, or ATU)
- Detecting or confirming antimicrobial resistant phenotypes such as ESBL, MBL, AmpC*, or GISA/hGISA*
*For Research Use Only
Extended-Range MICs Spanning 15 Two-Fold Dilutions
ETEST® provides full-range MICs spanning 15 two-fold dilutions for concentrations that are ideal for refining patient treatment in instances where routine AST methods are limited in one of the following ways:
- Provides S, I, or R category results only
- MIC results are off-scale (i.e., “<” or “>” results) and do not provide sufficient data for pharmacokinetic/pharmacodynamic (PK-PD) targeted dosing considerations
Easy-to-Use MIC Technique
ETEST® is easy to implement and use:
- No software or specific skills required
- Individual testing – perfectly adapted for MIC testing for newly launched antimicrobials
ETEST® Aztreonam/Avibactam (AZA)
Test strips rapidly, easily determine MIC level for Aztreonam/Avibactam susceptibility for Enterobacterales*.
Provide vital information for appropriate therapy decision for complicated infections** and to help reduce development of drug-resistant bacteria.
Making sure that patients get the right antimicrobial, in the right dose, at the right time is at the heart of antimicrobial stewardship.
- Confidence: Reliably monitor efficacy Aztreonam/Avibactam of treatment for complicated infections
- Fast time to result: 16 hours
- Accuracy: Determine exact Minimum Inhibitory Concentration (MIC) values of Aztreonam/Avibactam
Aztreonam/Avibactam, known by the trade name EMBLAVEO®, is used to treat certain multidrug-resistant Gram-negative infections. It is indicated for complicated intraabdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilatorassociated pneumonia (VAP), complicated urinary tract infections (cUTI), including pyelonephritis, and infections due to aerobic Gram-negative organisms with limited treatment options.
ETEST® AZA was developed by bioMérieux in collaboration with Pfizer, the producer of EMBLAVEO®.
REFERENCE : 424460 - ETEST® AZA (0.016/4-256/4 μg/mL)
*Enterobacterales: Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, Klebsiella aerogenes, Proteus mirabilis, Proteus vulgaris, Citrobacter koseri, Morganella morganii, Serratia marcescens, Providencia stuartii
** complicated infections: complicated intraabdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilatorassociated pneumonia (VAP), complicated urinary tract infections (cUTI), including pyelonephritis, and infections due to aerobic Gram-negative organisms with limited treatment options.
ETEST® SUD
ETEST® Sulbactam/Durlobactam (SUD) is a reliable new tool for Sulbactam/Durlobactam susceptibility testing in Acinetobacter baumannii-calcoaceticus complex.
Developed with our partner Innoviva™, ETEST® SUD aids in combating hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
This innovative solution provides a critical new option for managing CRAB (Carbapenem-Resistant Acinetobacter baumannii) infections, which was identified as a top priority by WHO due to its resistance and clinical challenges1.
ETEST® Sulbactam/Durlobactam (SUD) plays a vital role in guiding clinical decisions for effective treatment with Sulbactam/Durlobactam.
1. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance
- Filename
- Flyer-ETEST-SUD.pdf
- Size
- 1 MB
- Format
- application/pdf
REFERENCES ETEST(R) Sulbactam/Durlobactam (SUD) - (0.004/4-64/4 µg/mL)
WW market (excl. US) : 423575 US market only : 423613
Download Flyer
- Filename
- Flyer-ETEST-SUD.pdf
- Size
- 1 MB
- Format
- application/pdf